| Latest Xenoport News Headlines | | Date | Time | Source | | | 09/16/2008 | 8:00AM | PRNUS | GSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira(TM) for Restless Legs Syndrome
Submission Based on Results from Pivotal Trials Evaluating Efficacy, Safety and Maintenance of Effect in Patients with Moderate-to-Severe Primary RLS
RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., Sept. 16
/PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (NASDAQ:XNPT) announced today that... More...>> |
| 04/17/2008 | 3:15PM | PRNUS | Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Sever
Additional Data Demonstrate Predictable, Extended Exposure with Sustained- Release Formulation
CHICAGO, April 17 /PRNewswire/ -- Data from the first pivotal study of XP13512/GSK1838262, a sustained-release investigational compound to treat Restless Legs Syndrome (RLS), showed that it significantly improved the symptoms... More...>> |
| 11/10/2006 | 5:52PM | PRNUS | /C O R R E C T I O N -- XenoPort, Inc./
In the news release, XenoPort, Inc. (Nasdaq: XNPT) to Present at Upcoming Investor Conferences, issued Friday, Oct. 20, by XenoPort, Inc. over PR Newswire, we are advised by the company that the second paragraph, second bullet point, should read "Wednesday, November 15, 2006 at 6:00 p.m. Eastern Time," rather than "1:00... More...>> |
| 11/10/2006 | 5:52PM | PRNUS | /C O R R E C T I O N -- XenoPort, Inc./
In the news release, XenoPort, Inc. (Nasdaq: XNPT) to Present at Upcoming Investor Conferences, issued Friday, Oct. 20, by XenoPort, Inc. over PR Newswire, we are advised by the company that the second paragraph, second bullet point, should read "Wednesday, November 15, 2006 at 6:00 p.m. Eastern Time," rather than "1:00... More...>> |
| 10/22/2006 | 7:00PM | PRNUS | XenoPort Announces Positive Results From XP19986 Phase 2a Trial in Patients with Gastroesophageal Reflux Disease
Data Presented at the American College of Gastroenterology Meeting
SANTA CLARA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced that additional data from the company's Phase 2a single-dose clinical trial of XP19986 in patients with gastroesophageal reflux disease, or GERD, was presented... More...>> |
| 10/20/2006 | 11:00AM | PRNUS | XenoPort to Present at Upcoming Investor Conferences
SANTA CLARA, Calif., Oct. 20 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that it will provide access via the world wide web to its investor presentations at the following healthcare conferences:
-- Rodman & Renshaw 8th Annual Healthcare Conference
Tuesday, November 7, 2006 at 4:55... More...>> |
| 10/06/2006 | 1:53PM | PRNUS | XenoPort to Release Third Quarter Financial Results on November 2, 2006
SANTA CLARA, Calif., Oct. 6 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that it will release its third quarter financial results on November 2, 2006, at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the... More...>> |
| 09/05/2006 | 1:00PM | PRNUS | XenoPort to Present at Upcoming Investor Conferences
SANTA CLARA, Calif., Sept. 5 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that it will provide access via the world wide web to its presentations at the Bear Stearns 19th Annual Healthcare Conference and the ThinkEquity Partners Growth Conference. The company's presentation at the Bear Stearns... More...>> |
| 08/09/2006 | 4:05PM | PRNUS | XenoPort Reports Second Quarter Financial Results
SANTA CLARA, Calif., Aug. 9 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today financial results for the second quarter and six months ended June 30, 2006. Revenues for the quarter were $3.1 million, compared to $0.8 million for the same period in 2005. Net loss for the second quarter was $14.4... More...>> |
| 07/13/2006 | 4:00PM | PRNUS | XenoPort to Release Second Quarter Financial Results on August 9, 2006
SANTA CLARA, Calif., July 13 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that it will release its second quarter financial results on August 9, 2006, at 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available... More...>> |
| 06/21/2006 | 8:46PM | PRNUS | XenoPort Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock
SANTA CLARA, Calif., June 21 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today the pricing of a public offering of 4,500,000 shares of its common stock at $17.00 per share. All of the shares are being offered by the company. The company has granted to the underwriters a 30-day option to purchase... More...>> |
| 06/20/2006 | 8:30AM | PRNUS | XenoPort Announces Presentation of XP13512 Data at the Associated Professional Sleep Societies Meeting
SANTA CLARA, Calif., June 20 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that data from the company's previously reported Phase 2a clinical trial of XP13512 for the treatment of Restless Legs Syndrome, or RLS, will be presented by Clete A. Kushida, M.D., Ph.D., at the SLEEP 2006 20th Anniversary... More...>> |
| 06/06/2006 | 5:55PM | PRNUS | XenoPort Announces Public Offering of Common Stock
SANTA CLARA, Calif., June 6 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that it has filed a registration statement with the Securities and Exchange Commission for a public offering of 4,500,000 shares of its common stock. All of the shares will be offered by XenoPort.
XenoPort expects to... More...>> |
| 05/22/2006 | 8:30AM | PRNUS | XenoPort Reports Positive Preliminary Results from a Phase 2a Clinical Trial of XP19986 as a Treatment for Gastroesophageal Ref
SANTA CLARA, Calif., May 22 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today preliminary top-line results of a Phase 2a clinical trial indicating that single doses of XP19986 were well tolerated and produced statistically significant reductions in the number of reflux episodes in patients with... More...>> |
| 05/10/2006 | 4:05PM | PRNUS | XenoPort Reports First Quarter Financial Results
SANTA CLARA, Calif., May 10 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today its financial results for the first quarter ended March 31, 2006. Revenues for the quarter were $1.3 million, compared to $2.8 million for the same period in 2005. Net loss for the first quarter was $15.0 million, compared... More...>> |
| 05/04/2006 | 8:30AM | PRNUS | XenoPort Announces Presentation of XP13512 Data at the American Pain Society Meeting
SANTA CLARA, Calif., May 4 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that additional data from the company's Phase 2a clinical trial of XP13512 for the treatment of post-herpetic neuralgia, or PHN, will be presented by Miroslav Backonja, M.D., at the American Pain Society Annual Meeting... More...>> |
| 04/21/2006 | 10:00AM | PRNUS | XenoPort to Release First Quarter Financial Results on May 10, 2006
SANTA CLARA, Calif., April 21 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that it will release its first quarter financial results on May 10, 2006, at 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available... More...>> |
| 04/20/2006 | 5:02PM | PRNUS | XenoPort to Present at Upcoming Healthcare Conferences
SANTA CLARA, Calif., April 20 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that it will provide access via the world wide web to its presentations at the Deutsche Bank 2006 Health Care Conference and the Morgan Stanley Global Healthcare Unplugged Conference. The company's Deutsche Bank Conference... More...>> |
| 03/29/2006 | 8:30AM | PRNUS | XenoPort Announces Presentation of XP13512 Data at the American Academy of Neurology Meeting
SANTA CLARA, Calif., March 29 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that additional data from the company's Phase 2b clinical trial of XP13512 for the treatment of Restless Legs Syndrome, or RLS, will be presented by Clete A. Kushida, M.D., Ph.D., at the American Academy of Neurology... More...>> |
| 03/14/2006 | 8:30AM | PRNUS | XenoPort Initiates Phase 3 Clinical Program for XP13512 as a Treatment for Restless Legs Syndrome
Commencement Triggers $10 Million Milestone Payment From Astellas
SANTA CLARA, Calif., March 14 /PRNewswire-FirstCall/ -- XenoPort, Inc. (NASDAQ:XNPT) announced today that it has initiated its first Phase 3 clinical trial of XP13512 as a treatment for restless legs syndrome, or RLS. The commencement of this Phase 3... More...>> |
|